Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients

Abstract

BackgroundMonoclonal antibodies (mAbs) directed against Tumor Necrosis Factor alpha (TNF‐α) and interleukin (IL)‐17 and 23 represent the ultimate therapeutic strategy in treating psoriasis patients, but scientific literature still does not provide conclusive results regarding the possible influence of previous biological therapies on real‐life therapeutic response.ObjectivesThe objective of our work was to investigate any putative difference in the achievement and maintenance of PASI 75, 90 and 100, as well as the probability to achieve absolute PASI≤1 and ≤ 3, between 305 bio‐naïve and bio‐experienced patients treated with anti‐IL mAbs.MethodsA comparison between previous biologic and clinical factors, including relative and absolute PASI, was carried out through chi square test. Survival curves for the achievement of PASI 75, 90 and 100 and their differences were evaluated, performing a multivariate analysis (Confidence Interval 95%; p‐value <0.0.5).ResultsPrevious biologic therapy resulted associated with a lower rate of PASI 75 (HR 1,339; p‐value 0,034), 90 (HR 1,365; p‐value 0,0031;) and 100 achievement (HR 1,596; p‐value 0,007).The survival curves showed how bio‐experienced patients were less likely to reach and maintain PASI 90 (naïve vs anti‐IL: p = 0.001; naïve vs anti‐TNF + anti‐IL: p <0.001) and PASI 100 (naïve vs anti‐TNF‐α: p = 0.014; naïve vs anti‐IL: p <0.001; naïve vs anti‐TNF‐α + anti‐IL: p < 0.001)]. Moreover, bio‐naïve patients showed a greater probability to achieve both absolute PASI≤3 and ≤ 1 (p<0.001)ConclusionsOur results represent a real‐life analysis on the impact of previous biologic therapy in the clinical efficacy of anti‐IL. Even if further studies with bigger samples are needed to extrapolate absolute considerations, we provided the first evidence on the burden of the bio‐naïve condition for a greater achievement of both PASI 90, 100 and the probability to achieve PASI≤1 and ≤ 3.This article is protected by copyright. All rights reserved.